+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications

Therapeutic Apheresis and Dialysis 13(6): 534-539

Reducing sugars can react non-enzymatically with amino groups of protein to form Amadori products. These early glycation products undergo further complex reactions, such as rearrangement, dehydration, and condensation, to become irreversibly cross-linked, heterogeneous fluorescent derivatives, termed advanced glycation end products (AGEs). The formation and accumulation of AGEs have been known to progress at an accelerated rate in patients with diabetes mellitus, thus being involved in the development and progression of diabetic micro- and macroangiopathy. Indeed, there is accumulating evidence that an interaction between an AGE and its receptor (RAGE) generates oxidative stress and subsequently evokes vascular inflammation and thrombosis, thereby playing a central role in diabetic vascular complications. In this paper, we review the pathophysiological role of AGE-RAGE-oxidative stress system and its therapeutic interventions in diabetic micro- and macroangiopathy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051394822

Download citation: RISBibTeXText

PMID: 19954478

DOI: 10.1111/j.1744-9987.2009.00775.x

Related references

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs 17(7): 983-996, 2008

A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clinical Biochemistry 46(1-2): 109-114, 2013

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14: 2, 2016

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta 1820(5): 663-671, 2012

Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications. Journal of Diabetes Investigation 2(3): 155-157, 2011

Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. Journal of Diabetes Investigation 3(2): 107-114, 2012

Effects of advanced glycation end products and its receptor on oxidative stress in diabetic wounds. Zhonghua Shao Shang Za Zhi 28(1): 32-35, 2013

Possible participation of advanced glycation endproducts and their receptor system in the development of diabetic vascular complications. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 121(1): 49-55, 2003

Angiotensin II receptor antagonist reduces the accumulation of advanced glycation end products and oxidative/nitrosative stress in type 2 diabetic KK/Ta mice. Journal of the American Society of Nephrology 14(Abstracts Issue): 131A, 2003

Advanced glycation end-products induce oxidative stress through the Sirt1/Nrf2 axis by interacting with the receptor of AGEs under diabetic conditions. Journal of Cellular Biochemistry 2018, 2018

Advanced glycation end-products and the progress of diabetic vascular complications. Physiological Research 53(2): 131-142, 2004

Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Reviews 1(1): 93-106, 2008

Advanced Glycation End Products (Ages) and Diabetic Vascular Complications. Current Diabetes Reviews 1(1): 93-106, 2005

The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes and Metabolism Journal 42(3): 188-195, 2018

Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxidative Medicine and Cellular Longevity 3(2): 101-108, 2010